GlassScriptPhysician profile
Carlos A Charles
NPI 1760683833
$8,310.33
in general payments reported to CMS, 2019-2025
29 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $200 · 2021: $24.64 · 2022: $1,298 · 2023: $2,184 · 2024: $2,249 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,824 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,824.14 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,736.81 | 2019-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $1,132.95 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $931.81 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $639.45 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $610.66 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $402.00 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $342.12 | 2019-2025 | |
| Leo Pharma INC. | $321.48 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $310.69 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $288.99 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $249.29 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Celgene Corporation | $211.66 | 2019 | |
| Arcutis Biotherapeutics, INC. | $193.39 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $182.05 | 2019-2025 | Nemluvio |
| Pfizer INC. | $159.85 | 2019-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $135.82 | 2019-2023 | |
| Triad Life Sciences INC. | $88.22 | 2022 | |
| Fresenius Kabi USA, LLC | $46.13 | 2023 | Idacio |
| Mayne Pharma Commercial LLC | $44.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $41.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.62 | 2024 | Cyltezo, Spevigo |
| Journey Medical Corporation | $37.88 | 2022-2023 | |
| Dermavant Sciences, INC. | $33.82 | 2022-2024 | Vtama |
| Epi Health, LLC | $28.26 | 2022 | |
| Almirall LLC | $24.64 | 2021 | |
| Zimmer Biomet Holdings, INC. | $20.27 | 2022 | |
| Aclaris Therapeutics, INC. | $20.17 | 2019 | |
| Organon LLC | $19.26 | 2025 | Vtama |
| Dermira, INC. | $16.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.